Stock Monitor: Dermira Post Earnings Reporting
LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Reata Pharmaceuticals, Inc. (NASDAQ: RETA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RETA as the Company's latest news hit the wire. On May 25, 2018, the Company announced that it has presented results from the ongoing, open-label, Phase-2 PHOENIX trial assessing bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Dermira, Inc. (NASDAQ: DERM), which also belongs to the Healthcare sector as the Company Reata Pharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Reata Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Primary Endpoint of PHOENIX Study is Change from Baseline in eGFR after 12 Weeks of Treatment
The Phase-2 PHOENIX program is studying bardoxolone in patients with ADPKD, IgA nephropathy, focal segmental glomerulosclerosis, and chronic kidney disease (CKD) associated with type-1 diabetes. The primary efficacy endpoint of the study is change from baseline in eGFR after 12 weeks of treatment. The ADPKD cohort of PHOENIX enrolled 31 patients, and available data demonstrate that bardoxolone significantly improved kidney function in ADPKD patients as measured by their estimated glomerular filtration rate (eGFR). Bardoxolone-treated patients showed a mean improvement of 6.6 mL/min/1.73 m2 at Week 4, increasing to 12.0 mL/min/1.73 m2 at Week 12. The IgA nephropathy cohort enrolled 26 patients, and data were reported through Week 8. Bardoxolone-treated patients showed a mean improvement of 8.4 mL/min/1.73 m2 at Week 8 from a mean baseline eGFR of 46.2 mL/min/1.73 m2. No drug-related serious adverse events have been reported.
Full data for the primary endpoint of change in eGFR at Week 12 for the ADPKD, IgA nephropathy, and type-1 diabetic CKD cohorts of PHOENIX will be available in Q3 2018.
Bardoxolone May Delay Onset of Kidney Failure in Patients with Type-2 Diabetes & Stage 4 CKD
An oral presentation entitled ''Bardoxolone Methyl Prevents eGFR Decline in Patients with Chronic Kidney Disease Stage 4 and Type-2 Diabetes - Post-hoc Analyses from BEACON'' was also given. The analysis demonstrated that patients randomized to bardoxolone were more than 50% less likely than patients receiving placebo to experience events that predict kidney failure. The authors of the abstract concluded that bardoxolone preserves kidney function and may delay the onset of kidney failure in patients with type-2 diabetes and stage 4 CKD. The abstract was named a Ten Best Abstract by the Paper Selection Committee of ERA-EDTA.
About Bardoxolone Methyl
Bardoxolone is an experimental, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted orphan designation to bardoxolone for the treatment of Alport syndrome and for the treatment of connective tissue disease associated pulmonary arterial hypertension.
About Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy
ADPKD is a genetic form of CKD caused by mutations in PKD1 and PKD2 genes leading to inflammation that stimulates the formation of fluid-filled cysts in the kidneys that cause pain and progressive loss of kidney function.
IgA nephropathy, also known as Berger's disease, is a rare form of CKD that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. There are currently no FDA-approved therapies for IgA nephropathy.
About Reata Pharmaceuticals, Inc.
Founded in 2002 and headquartered in Irving, Texas, Reata Pharma is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.
Stock Performance Snapshot
May 29, 2018 - At Tuesday's closing bell, Reata Pharma's stock rose 1.73%, ending the trading session at $34.19.
Volume traded for the day: 145.36 thousand shares.
Stock performance in the last month - up 30.50%; previous three-month period - up 36.71%; past twelve-month period - up 26.63%; and year-to-date - up 20.73%
After yesterday's close, Reata Pharma's market cap was at $904.67 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the ''Author'') and is fact checked and reviewed by a third-party research service company (the ''Reviewer'') represented by a credentialed financial analyst. For further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the ''Sponsor''), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.